ORYX' Oncolytic Virus ParvOryx Successfully Completes Phase I/IIa Trial to Treat Glioblastoma Multiforme
ORYX announced the successful completion of the Phase I/IIa trial ParvOryx with the oncolytic parvovirus H1 to treat patients with progressive primary or recurrent glioblastoma. The open label, single center trial included 18 patients (UICC Stage IV), who showed recurrent or progressive disease despite previous radio- and/or chemotherapy. As primary endpoints, the trial evaluated safety, maximum tolerated dose, viremia and virus shedding. Secondary endpoints were efficacy, progression-free survival up to six months and overall survival. The vaccine was safe and strong cellular immune responses were observed. Full data from the trial will be presented at upcoming scientific conferences.
Oncolytic parvovirus H1 (H-1PV) is a wild type rat virus that infects and lyses tumor cells from a wide variety of human tumors. H-1PV is also able to cross the blood brain barrier.
Unlike other natural or modified oncolytic viruses currently under investigation, H-1PV does not affect normal cells and is not pathogenic to humans. H-1PV acts at relatively low multiplicities of infection. The virus exerts a cytotoxic/oncolytic effect, predominantly mediated by the non-structural protein (NS1). In addition, viral oncolysis induces a strong and lasting tumor-specific immune response (bystander effect).
Other news from the department research and development
